| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-4-fluoro-1-piperidinyl]- | [CAS]
1415823-49-2 | [Synonyms]
M7583,M-7583
TL-895, M7583
2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-4-fluoro-1-piperidinyl]-
anti-viral,TL-895,Inhibitor,Bruton tyrosine kinase,TL895,Myelofibrosis,Solid Tumor,Carcinoma,Acute Myeloid Leukemia,Btk,Cancer,TL 895,Sars-CoV2,COVID-19,inhibit | [Molecular Formula]
C25H26FN5O2 | [MDL Number]
MFCD34567755 | [MOL File]
1415823-49-2.mol | [Molecular Weight]
447.5 |
| Chemical Properties | Back Directory | [Boiling point ]
685.0±55.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (558.66 mM; Need ultrasonic) | [form ]
Solid | [pka]
5.29±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively[1]. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research[2][3][4]. | [References]
[1] Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655. DOI:10.1021/acs.jmedchem.9b00794
[2] Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci DOI:10.3390/ijms22020561
[3] A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
[4] Study of TL-895 in Subjects With Myelofibrosis |
|
|